Engineered repressors are potent inhibitors of androgen receptor activity

Oncotarget

Volumn 5, Issue 4, 2014, Pages 959-969

  Brooke, Greg N ^a,b   Powell, Sue M ^a   Lavery, Derek N ^a   Waxman, Jonathan ^a   Buluwela, Laki ^a   Ali, Simak ^a   Bevan, Charlotte L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Androgen receptor; Anti androgen; Castrate resistant prostate cancer; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; STEROID RECEPTOR COACTIVATOR 1; ANDROGEN RECEPTOR ANTAGONIST; AR PROTEIN, HUMAN; HYBRID PROTEIN; REPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ENGINEERING; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 84897432490     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1360     Document Type: Article

References (47)

1. Robinson-Rechavi M, Escriva Garcia H and Laudet V. The nuclear receptor superfamily. J Cell Sci. 2003; 116(Pt 4):585-586.
2. Jenster G, van der Korput JA, Trapman J and Brinkmann AO. Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol. 1992; 41(3-8):671-675.
3. Lonergan PE and Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011; 10:20.
4. Langley E, Kemppainen JA and Wilson EM. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem. 1998; 273(1):92-101.
5. Callewaert L, Verrijdt G, Christiaens V, Haelens A and Claessens F. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J Biol Chem. 2003; 278(10):8212-8218.
6. He B, Lee LW, Minges JT and Wilson EM. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem. 2002; 277(28):25631-25639.
7. Heery DM, Kalkhoven E, Hoare S and Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387(6634):733-736.
8. Bevan C and Parker M. The role of coactivators in steroid hormone action. Exp Cell Res. 1999; 253(2):349-356.
9. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, Ziel-van der Made AC, Brinkmann AO, Pike AC and Trapman J. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol. 2004; 18(9):2132-2150.
10. Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ and Guy RK. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem. 2005; 280(9):8060-8068.
11. Brooke GN, Parker MG and Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene. 2008; 27(21):2941-2950.
12. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM and Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol. 2004; 2(9):E274.
13. Hodgson MC, Shen HC, Hollenberg AN and Balk SP. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol Cancer Ther. 2008; 7(10):3187-3194.
14. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997; 389(6652):753-758.
15. Masiello D, Cheng S, Bubley GJ, Lu ML and Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277(29):26321-26326.
16. Nagy L, Kao HY, Love JD, Li C, Banayo E, Gooch JT, Krishna V, Chatterjee K, Evans RM and Schwabe JW. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 1999; 13(24):3209-3216.
17. Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC and Bevan CL. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin Cancer Res. 2004; 10(21):7392-7401.
18. Saraon P, Jarvi K and Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011; 57(10):1366-1375.
19. Zhang P, Zhang J, Young CY, Kao PC, Chen W, Jiang A, Zhang L and Guo Q. Decoy androgen-responsive element DNA can inhibit androgen receptor transactivation of the PSA promoter gene. Ann Clin Lab Sci. 2005; 35(3):278-284.
20. Minamiguchi K, Kawada M, Ohba S, Takamoto K and Ishizuka M. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004; 214(1-2):175-187.
21. van de Wijngaart DJ, Dubbink HJ, Molier M, de Vos C, Jenster G and Trapman J. Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection. Prostate. 2011; 71(3):241-253.
22. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res. 2011; 71(4):1208-1213.
23. Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D and Baniahmad A. A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode. Endocrinology. 2011; 152(6):2174-2183.
24. Ayer DE, Laherty CD, Lawrence QA, Armstrong AP and Eisenman RN. Mad proteins contain a dominant transcription repression domain. Mol Cell Biol. 1996; 16(10):5772-5781.
25. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ and Rauscher FJ, 3rd. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A. 1994; 91(10):4509-4513.
26. Pike J, Holmes D, Kamalati T, Davies D, Tolhurst R, Mazhar D, Fishpool S, al-Jehani R, Waxman J, Zelent A, Lemoine NR, Ali S and Buluwela L. Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor. Oncogene. 2004; 23(45):7561-7570.
27. He B, Kemppainen JA, Voegel JJ, Gronemeyer H and Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem. 1999; 274(52):37219-37225.
28. Peterziel H, Mink S, Schonert A, Becker M, Klocker H and Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999; 18(46):6322-6329.
29. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS and Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61(11):4315-4319.
30. Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM and Bevan CL. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res. 2011; 71(3):914-924.
31. Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B and Bevan CL. Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors. J Biol Chem. 2011; 286(20):17796-17808.
32. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL and Parker MG. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol. 2005; 25(4):1425-1436.
33. Elmore LW, Forsythe R, Forsythe H, Bright AT, Nasim S, Endo K and Holt SE. Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas. Oncol Rep. 2008; 20(3):613-617.
34. Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J and Chang C. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem. 2004; 279(32):33438-33446.
35. Brooke GN and Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics. 2009; 10(1):18-25.
36. Brooke GN and Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics. 2009; 10(1):18-25.
37. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW and Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994; 54(11):2861-2864.
38. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994; 57(3):406-412.
39. Tsao CK, Galsky MD, Small AC, Yee T and Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012; 110(11):1580-1588.
40. Minamiguchi K, Kawada M, Ohba S, Takamoto K and Ishizuka M. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004; 214(1-2):175-187.
41. He B and Wilson EM. Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol. 2003; 23(6):2135-2150.
42. He B and Wilson EM. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab. 2002; 75(4):293-298.
43. Kalkhoven E, Valentine JE, Heery DM and Parker MG. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 1998; 17(1):232-243.
44. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH, Mulder E and et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989; 34(1-6):307-310.
45. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J and Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol. 1991; 5(10):1396-1404.
46. Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC and Bevan CL. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens. Clin Cancer Res. 2004; 10(21):7392-7401.
47. Kawano Y, Diez S, Uysal-Onganer P, Darrington RS, Waxman J and Kypta RM. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer. Br J Cancer. 2009; 100(7):1165-1174.